270 related articles for article (PubMed ID: 12918750)
1. Treatment of ocular manifestations of Behçet's disease.
Davatchi F
Adv Exp Med Biol; 2003; 528():487-91. PubMed ID: 12918750
[No Abstract] [Full Text] [Related]
2. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
3. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN.
Kotter I; Deuter C; Stubiger N; Zierhut M
J Rheumatol; 2005 Aug; 32(8):1633; author reply 1634. PubMed ID: 16078350
[No Abstract] [Full Text] [Related]
4. Uveitis in juvenile Behçet's disease: clinical course and visual outcome compared with adult patients.
Kramer M; Amer R; Mukamel M; Snir M; Jaouni T; Friling R
Eye (Lond); 2009 Nov; 23(11):2034-41. PubMed ID: 19151650
[TBL] [Abstract][Full Text] [Related]
5. Behçet's syndrome.
Stanford MR
Br J Ophthalmol; 2003 Apr; 87(4):381-2. PubMed ID: 12642292
[No Abstract] [Full Text] [Related]
6. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
Lee RW; Dick AD
Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
[No Abstract] [Full Text] [Related]
7. Evidence-based treatment of Behçet's syndrome.
Yurdakul S
Clin Exp Rheumatol; 2006; 24(5 Suppl 42):S53-5. PubMed ID: 17067428
[No Abstract] [Full Text] [Related]
8. [Prognostic factors of ocular involvement in Behçet's disease].
Belkhadir K; Boutimzine N; Laghmari M; Amazouzi A; Tachfouti S; Cherkaoui O
J Fr Ophtalmol; 2019 Jun; 42(6):612-617. PubMed ID: 31088739
[TBL] [Abstract][Full Text] [Related]
9. [Uveitic glaucoma in Behçet's disease: When everything gets complicated].
Belkhadir K; Boutimzine N; Tachfouti S; Laghmari M; Amazouzi A; Cherkaoui O
J Fr Ophtalmol; 2020 Sep; 43(7):635-641. PubMed ID: 32622636
[TBL] [Abstract][Full Text] [Related]
10. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
Park JY; Chung YR; Lee K; Song JH; Lee ES
Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
12. Eye and Behçet's disease.
Ksiaa I; Abroug N; Kechida M; Zina S; Jelliti B; Khochtali S; Attia S; Khairallah M
J Fr Ophtalmol; 2019 Apr; 42(4):e133-e146. PubMed ID: 30850197
[TBL] [Abstract][Full Text] [Related]
13. Behçet's syndrome: from aetiology to treatment.
Powell RJ
Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
[No Abstract] [Full Text] [Related]
14. Behçet's disease.
Yesudian PD; Edirisinghe DN; O'Mahony C
Int J STD AIDS; 2007 Apr; 18(4):221-7. PubMed ID: 17509169
[TBL] [Abstract][Full Text] [Related]
15. [Ocular prognosis in Behçet's disease].
Cochereau-Massin I; Wechsler B; Le Hoang P; Le Thi Huong Du; Girard B; Rousselie F; Godeau P
J Fr Ophtalmol; 1992; 15(5):343-7. PubMed ID: 1430813
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Behçet's disease.
Mochizuki M
Int Rev Immunol; 1997; 14(1):49-66. PubMed ID: 9203026
[TBL] [Abstract][Full Text] [Related]
18. Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects.
Tognon S; Graziani G; Marcolongo R
Ann N Y Acad Sci; 2007 Sep; 1110():474-84. PubMed ID: 17911463
[TBL] [Abstract][Full Text] [Related]
19. [Eye and Behçet's disease].
Binisti P
Rev Prat; 1999 Nov; 49(18):1999-2003. PubMed ID: 10626485
[TBL] [Abstract][Full Text] [Related]
20. Antitumor necrosis factor monoclonal antibody therapy in a woman with severe Adamantiades-Behçet's disease.
Behrens F; Zollner T; Moeller B; Kaltwasser JP; Kaufmann R; Ochsendorf FR
Adv Exp Med Biol; 2003; 528():561-2. PubMed ID: 12918764
[No Abstract] [Full Text] [Related]
[Next] [New Search]